EPRX — Eupraxia Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- CA$191.44m
- CA$187.33m
Annual income statement for Eupraxia Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | USG | USG | USG |
| Status: | fx Final | fx Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 1.68 | 16.7 | 17.6 | 27.8 | 27 |
| Operating Profit | -1.68 | -16.7 | -17.6 | -27.8 | -27 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -2.99 | -18.6 | -19 | -28.9 | -25.7 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -2.99 | -18.6 | -19 | -29 | -25.7 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -2.98 | -18.3 | -18.5 | -28.2 | -25.5 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -2.98 | -18.3 | -18.5 | -28.2 | -25.5 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.224 | -1.3 | -0.947 | -1.16 | -0.722 |
| Dividends per Share |